Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Dali cargo ship is finally brought back to port
Public Private Partnerships for flood protection would only add to costs
How endangered dolphins could shut down the SailGP
Auckland Airport expects the population of a city during school holidays
Culture festival showcases integration
Strong winds linger after storm blows through much of country
Haiti PM Ariel Henry in Puerto Rico as gang violence continues
Public Private Partnerships for flood protection would only add to costs
Should you claim child benefit? What it's worth
Threat of fire increasing concern for Christchurch Adventure Park
Wildfires sweep across Finland, straining rescue services
Auckland Airport expects the population of a city during school holidays